Also, we have established a process where session speakers can do an internal mock presentation prior to the actual AMCP meeting
TL;DR: The GLP-1 receptor agonist landscape in 2026 spans four distinct compounds: semaglutide (selective GLP-1 RA, MW 4113.58 Da, injectable and oral), tirzepatide (dual GLP-1/GIP agonist, MW 4813.45 Da), retatrutide (triple GLP-1/GIP/glucagon agonist, MW ~4500 Da, Phase 3), and orforglipron (non-peptide oral GLP-1 agonist, MW 541.65 Da, FDA-approved April 2026)
Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: A systematic review and meta-analysis
Last updated 10/19/2015
Microdosing GLP-1 drugs for weight loss is growing in popularity among Americans looking to save a little money or reduce gastrointestinal side effects
Petechiae, cherry angiomas, heat rash, medication reactions, infections, and platelet problems can cause tiny red dots